Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared a post on X:
“Building off of Nancy Lin and Dr Pablo Leone’s data with carboplatin/bevacizumab in brain metastases.
77% intracranial response rate of carbo, bev, and PD-1 inhibition in TNBC brain metastases shows excellent potential.
Time to try this with bispecifics.”
More posts featuring ASCO25.
